Brancaccio D, Gallieni M, Pasho S, Fallabrino G, Olivi L, Volpi E, Ciceri P, Missaglia E, Ronga C, Brambilla C, Butti A, Rocca-Rey L, Chiarelli G, Cozzolino M
Cattedra di Nefrologia, U.O. Nefrologia e Dialisi, A.O. San Paolo, Milano 20142, Italy.
G Ital Nefrol. 2009 Mar-Apr;26 Suppl 45:S20-7.
Increased vascular calcification is a major cause of cardiovascular events in patients with chronic kidney disease (CKD). It is the result of an active ossification process counteracted by ''bone'' proteins such as osteopontin, alkaline phosphatase, osteoprotegerin, and osteocalcin. Chronic kidney disease - mineral and bone disorder (CKD-MBD) is a systemic disorder of mineral and bone metabolism that occurs in CKD. In addition to abnormalities in the serum calcium and phosphate profile, CKD-MBD is characterized by abnormalities of bone turnover, mineralization, volume and growth as well as vascular calcification. Considering that the presence and extent of vascular calcification in CKD portend a poor prognosis, many efforts have been made to shed light on this complicated phenomenon to prevent vascular calcium deposition and its progression. Indeed, careful control of calcium load, serum phosphate and parathyroid hormone along with the use of calcium-free phosphate binders and vitamin D receptor activators represent a new therapeutic armamentarium to improve quality of life and reduce mortality in CKD.
血管钙化增加是慢性肾脏病(CKD)患者心血管事件的主要原因。它是由诸如骨桥蛋白、碱性磷酸酶、骨保护素和骨钙素等“骨”蛋白对抗的活跃骨化过程的结果。慢性肾脏病 - 矿物质和骨异常(CKD-MBD)是一种发生在CKD患者中的矿物质和骨代谢的全身性疾病。除了血清钙和磷水平异常外,CKD-MBD的特征还包括骨转换、矿化、体积和生长异常以及血管钙化。鉴于CKD中血管钙化的存在和程度预示着不良预后,人们已经做出了许多努力来阐明这一复杂现象,以防止血管钙沉积及其进展。事实上,仔细控制钙负荷、血清磷和甲状旁腺激素,同时使用无钙磷结合剂和维生素D受体激活剂,代表了一种新的治疗手段,可改善CKD患者的生活质量并降低死亡率。